<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pylephlebitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pylephlebitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pylephlebitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pylephlebitis, or infective suppurative thrombosis of the portal vein, is a serious condition with significant morbidity and mortality, which can complicate intra-abdominal sepsis of any etiology. Although universally fatal in the pre-antibiotic era [<a href="#rid1">1</a>], the outcome of this infection has improved somewhat with modern diagnostic and therapeutic modalities. Curiously, however, reports of the diagnosis have increased in the last 15 years, possibly as a result of newer, more sensitive imaging techniques [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The portal vein is formed by the union of the superior mesenteric with the splenic veins. The portal system drains blood from the abdominal section of the gastrointestinal tract, with the exception of the lower part of the rectum.</p><p>Pylephlebitis begins with thrombophlebitis of small veins draining an area of infection. Extension of the thrombophlebitis into larger veins leads to septic thrombophlebitis of the portal vein, which can extend further to involve the mesenteric veins [<a href="#rid4">4</a>]. In a review of case reports, the superior mesenteric vein was involved in 42 percent [<a href="#rid5">5</a>]. Thrombus involved the splenic vein and intrahepatic branches of the portal vein in 12 and 39 percent of cases, respectively. Mesenteric vein involvement can lead to bowel ischemia, infarction and death.</p><p>An associated hypercoagulable state is found in some cases of pylephlebitis [<a href="#rid6">6</a>]. As an example, in one series of 44 cases, 18 were hypercoagulable due to clotting factor deficiencies, malignant conditions, or HIV/AIDS [<a href="#rid7">7,8</a>]. However, in another study that included 33 patients who underwent testing for a hypercoagulable condition in the setting of pylephlebitis, the rate of positive tests was low and results did not impact management [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Pylephlebitis can complicate any intra-abdominal or pelvic infection that occurs in the region drained by the portal venous system, especially diverticulitis and appendicitis (<a class="graphic graphic_figure graphicRef71532" href="/d/graphic/71532.html" rel="external">figure 1</a>) [<a href="#rid2">2,7,10,11</a>]. In a 1948 report, the most common inciting infection was appendicitis, accounting for all 21 cases [<a href="#rid12">12</a>]. However, the incidence of pylephlebitis following appendicitis significantly decreased with the introduction of antibiotics [<a href="#rid1">1</a>]. One of the most frequent foci is diverticulitis, which accounted for 6 of 18 cases in one series [<a href="#rid2">2</a>]. Although diverticulitis is a common cause of pylephlebitis, pylephlebitis remains a rare complication of diverticulitis [<a href="#rid1">1</a>]. In a 2023 systematic review of published cases between 1971 and 2022, diverticulitis (26.5 percent) and appendicitis (22 percent) were the two most common underlying causes of pylephlebitis [<a href="#rid3">3</a>]. </p><p>Contiguous infection (eg, cholangitis or infected choledocholithiasis) can also lead to this complication [<a href="#rid2">2,13</a>]. In addition, pylephlebitis has been associated with inflammatory bowel disease [<a href="#rid10">10,14-18</a>], pancreatitis [<a href="#rid5">5,19</a>], hemorrhoidal banding [<a href="#rid20">20</a>], transrectal prostate biopsy [<a href="#rid21">21</a>], and sigmoid colonic polypectomy [<a href="#rid22">22</a>]; it has also occurred as a complication of the intragastric migration of a silicone gastric band [<a href="#rid23">23</a>] and following a computed tomography (CT)-guided liver biopsy [<a href="#rid24">24</a>]. A precipitating focus was identified in 13 of 18 cases (68 percent) in one report [<a href="#rid2">2</a>]. Pylephlebitis due to <em>Bacteroides</em> in a patient with <em>Strongyloides</em> infection has also been reported [<a href="#rid25">25</a>]. In Taiwan, primary liver abscess due to <em>Klebsiella pneumoniae</em> has emerged as a precipitating factor for pylephlebitis [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/3124.html" rel="external">"Invasive liver abscess syndrome caused by Klebsiella pneumoniae"</a>.) </p><p>Pylephlebitis is more common in males and the age range of affected patients is wide (6 to 75 years), which may partially be influenced by the number of patients with appendicitis as an inciting etiology [<a href="#rid3">3</a>]. The mean age of patients with pylephlebitis is approximately 42 years, and in one review, 24 percent were aged &lt;18 years [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H4"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>Bacteremia associated with pylephlebitis is frequently polymicrobial. In a 2023 systematic review of 220 cases, positive blood cultures were reported in 70 percent of cases; of these, 61 percent had a single pathogen and 39 percent had polymicrobial infection [<a href="#rid3">3</a>]. In another review of 19 cases, bacteremia occurred in 88 percent. The most common bloodstream isolates were <em>Bacteroides fragilis</em>, <em>Escherichia coli</em>,<em> </em>and<em> streptococcus </em>spp, but other organisms (eg, <em>Aeromonas hydrophila</em>, streptococci, <em>Proteus mirabilis</em>, <em>K. pneumoniae</em>, anaerobic streptococci, and <em>Clostridium</em> spp) were also isolated [<a href="#rid2">2</a>]. <em>Fusobacterium</em>, <em>Parvimonas</em>, and <em>Actinomyces</em> have also been reported [<a href="#rid27">27-29</a>]. In another series of 95 cases, bacteremia occurred in 44 percent, and the most common isolate was <em>Streptococcus viridans </em>[<a href="#rid19">19</a>]. <em>Histoplasma</em> pylephlebitis has also been described in a liver transplant recipient [<a href="#rid30">30</a>].</p><p>Yeasts, other streptococci, staphylococci, and <em>Citrobacter </em>spp have also been described, but enterococci are an uncommon cause of this entity [<a href="#rid2">2,7</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Abdominal pain, which is not necessarily severe, and fever are the most common presenting symptoms of pylephlebitis. In one report, all 44 patients had these two complaints [<a href="#rid7">7</a>]. By contrast, 100 percent had fever but only 14 (74 percent) complained of abdominal pain in another review of 19 cases [<a href="#rid2">2</a>], and in another study of 67 patients, 87 percent had abdominal pain and 70 percent had fever [<a href="#rid9">9</a>]. In a 2023 review of 220 cases, 76 percent had fever and 65 percent had abdominal pain [<a href="#rid3">3</a>]. Other symptoms have included rigors, nausea, vomiting, and headache [<a href="#rid1">1,2,31</a>]. </p><p>Physical examination may elicit right upper quadrant or generalized abdominal tenderness, hepatomegaly, and jaundice. However, jaundice appears to be unusual in pylephlebitis unless there is associated cholangitis or liver abscess [<a href="#rid2">2</a>]. Splenomegaly has been reported in 10 to 25 percent of cases of pylephlebitis [<a href="#rid5">5,32</a>].</p><p>Patients may have minimal or no clinical features referable to the primary focus of infection, similar to patients with liver abscess [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/d/html/2680.html" rel="external">"Pyogenic liver abscess"</a>). Although pylephlebitis usually presents as an acute illness, it may also present with a chronic or stuttering course over weeks [<a href="#rid4">4,33</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Leukocytosis is a common finding [<a href="#rid1">1,9,14,31,34</a>], but both a normal leukocyte count [<a href="#rid2">2,32,34</a>] and neutropenia [<a href="#rid10">10</a>] have been described. Abnormal liver function tests, especially three- to fourfold increases in alkaline phosphatase [<a href="#rid1">1,10,14,31</a>] and 5- to 10-fold increases in gamma glutamyl transferase [<a href="#rid11">11,14</a>], are noted in most patients [<a href="#rid1">1</a>]. However, in keeping with the relative infrequency of clinical jaundice, two- to sixfold increases in serum bilirubin occur only in selected cases [<a href="#rid1">1,10,14,31</a>]. The inciting intra-abdominal sepsis or complicating hepatic abscesses may also contribute to hepatic dysfunction.</p><p class="headingAnchor" id="H7"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Pyogenic liver abscesses can complicate cases of pylephlebitis; in one series, they were reported in 37 percent of cases [<a href="#rid1">1,5,35-37</a>]. Bowel ischemia has also rarely been reported with one case of small bowel infarction necessitating bowel resection [<a href="#rid5">5,6</a>]. Portal hypertension may be a long term complication of pylephlebitis and has been described in a small number of cases [<a href="#rid5">5,10</a>]. Further sequelae of portal hypertension can include a dilated splenic vein and numerous venous collaterals in the hepatoduodenal ligament [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/2680.html" rel="external">"Pyogenic liver abscess"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of pylephlebitis requires the demonstration of portal vein thrombosis (pylethrombosis) usually accompanied by bacteremia in a febrile patient [<a href="#rid34">34</a>]. The diagnosis is frequently delayed because pylephlebitis is not considered since it is an uncommon condition, or because symptoms are nonspecific, clinical signs are typically lacking from the primary focus of infection, and there may be poor visualization of the portal vein. The diagnosis was most often made at laparotomy or postmortem in the past, but modern imaging techniques now facilitate an earlier diagnosis.</p><p class="headingAnchor" id="H9"><span class="h2">Blood cultures</span><span class="headingEndMark"> — </span>Bacteremia has been documented in 23 to 88 percent of cases [<a href="#rid2">2,7,9,19</a>]. For this reason, blood cultures should be obtained in any febrile patient with abdominal pain, optimally before initiation of antimicrobial therapy.</p><p class="headingAnchor" id="H10"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>The demonstration of thrombus in the portal vein is an important component of the diagnosis of pylephlebitis but is not sufficient by itself. The diagnostic imaging modality of choice depends on the expertise at the institution where the studies are performed. Both computed tomography (CT) scanning and ultrasonography can demonstrate thrombus in the portal vein (<a class="graphic graphic_diagnosticimage graphicRef91203" href="/d/graphic/91203.html" rel="external">image 1</a>), with or without associated mesenteric vein thrombus [<a href="#rid32">32</a>]. In up to 18 percent of cases, gas can be visualized in the portal system [<a href="#rid5">5</a>]. We prefer the CT scan as the imaging study because of the additional ability to identify an underlying focus of infection elsewhere in the abdomen or pelvis.</p><p class="headingAnchor" id="H11"><span class="h3">Computed tomography</span><span class="headingEndMark"> — </span>The CT scan is diagnostic when it demonstrates portal vein thrombosis in a patient with a clinical picture consistent with pylephlebitis (<a class="graphic graphic_diagnosticimage graphicRef91203" href="/d/graphic/91203.html" rel="external">image 1</a>) [<a href="#rid1">1,32,38</a>]. CT scanning has also been useful in defining a precipitating focus of infection.</p><p class="headingAnchor" id="H12"><span class="h3">Ultrasound</span><span class="headingEndMark"> — </span>Ultrasonography can demonstrate echogenic material within the lumen of the portal vein and can also be used to evaluate progression or extension of clot and subsequent recanalization [<a href="#rid10">10</a>]. Color flow Doppler ultrasonography may improve diagnostic accuracy [<a href="#rid1">1</a>]. Intraoperative ultrasonography has also been used to confirm the diagnosis of pylephlebitis when this entity is suspected preoperatively [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H433921002"><span class="h3">Other studies</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) has been used to demonstrate portomesenteric vein thrombosis [<a href="#rid9">9,19</a>]. There are occasional but limited reports of fluorodeoxyglucose positron emission tomography (FDG-PET) being useful in the diagnosis of pylephlebitis in patients with fever of unknown origin [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H13"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Antibiotics constitute the major treatment approach to pylephlebitis.</p><p class="headingAnchor" id="H14"><span class="h2">Antibiotics</span><span class="headingEndMark"> — </span>The choice of empiric antibiotics in pylephlebitis depends on the probable source of infection and the likely organisms (see <a class="local">'Microbiology'</a> above). Infection is often polymicrobial, with both gram-negative aerobes and anaerobes, especially <em>B. fragilis</em>. Successful antibiotic regimens have included <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> [<a href="#rid40">40</a>], third generation cephalosporins [<a href="#rid10">10</a>], fluoroquinolones [<a href="#rid10">10</a>], <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid10">10</a>], <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> [<a href="#rid2">2</a>], <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> [<a href="#rid2">2</a>], and <a class="drug drug_general" data-topicid="10113" href="/d/drug information/10113.html" rel="external">lincomycin</a> (not available in the United States) [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Recommended regimens</span><span class="headingEndMark"> — </span>Pylephlebitis is an uncommon infection, and thus, no randomized controlled studies have evaluated empiric antibiotic regimens for this disease. Treatment regimens are based on coverage of the most likely organisms to cause infection in this setting and small case series. We recommend that empiric treatment include broad-spectrum antibiotics until culture results are available. Patients should be treated at least initially with parenteral antibiotics.</p><p>Appropriate antibiotics include any of the following parenteral regimens:</p><p class="bulletIndent1"><span class="glyph">●</span>Combination therapy with <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg every eight hours) PLUS one of the following, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (2 g daily) OR <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> (2 g every six hours) OR <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (400 mg every 12 hours) OR <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> (500 mg daily)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> (4.5 g every six hours) OR <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> (3 g every six hours)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monotherapy with a carbapenem, such as <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> (500 mg every six hours) OR <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> (1 g every eight hours) OR <a class="drug drug_general" data-topicid="8675" href="/d/drug information/8675.html" rel="external">ertapenem</a> (1 g daily)</p><p></p><p>The initial antibiotic choice should be modified if blood or surgical (from the underlying focus of infection) culture results and antimicrobial susceptibility testing are available. Susceptibility testing for anaerobes are not routinely performed but should be considered, especially in patients who are failing therapy.</p><p class="headingAnchor" id="H16"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>The typical duration of antibiotic therapy is at least four to six weeks [<a href="#rid2">2</a>]. Parenteral antibiotics are given until there is significant clinical response, usually about two to three weeks. The remainder of the antibiotic course can be completed with oral agents, such as the combination of oral <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> and a fluoroquinolone.</p><p class="headingAnchor" id="H17"><span class="h2">Anticoagulation for select patients</span><span class="headingEndMark"> — </span>There are no prospective randomized controlled studies and no consensus on the use of anticoagulation in pylephlebitis. We do not use anticoagulation for all patients with pylephlebitis. However, we suggest anticoagulation for patients who have progression of thrombosis on repeat imaging or continued fever or bacteremia despite antibiotic therapy. Thrombosis that extends beyond the portal vein into the mesenteric vein on initial evaluation and an underlying hypercoagulable state are additional potential indications for anticoagulation. Since <em>Bacteroides</em> spp appear to promote coagulation, possibly through production of enzymes that break down heparin, as well as bacterial surface components that promote fibrin clotting [<a href="#rid4">4</a>], we are more likely to anticoagulate patients when this organism is isolated. </p><p>When anticoagulation is given, the optimal approach is uncertain. We typically initiate anticoagulation with low-molecular-weight heparin (LMWH). If needed (eg, on discharge), LMWH can be switched to an oral anticoagulant There have also been reports of the use of direct oral anticoagulants (DOACs) including <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> for initial anticoagulation [<a href="#rid28">28</a>]. Doses are similar to those used for other venous thromboembolic conditions and are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation", section on 'Anticoagulant agents'</a>.) </p><p>The duration of anticoagulation is also uncertain. It is reasonable to discontinue anticoagulation once the patient has improved clinically and imaging suggests that the thrombus is stable and not extending. Although this may occur within two to four weeks, patients often receive anticoagulation for at least three months [<a href="#rid9">9</a>]. Recanalization has been documented in some cases, but the length of time required for this to occur is unknown. One study suggested a mean time to thrombosis resolution of four and a half months [<a href="#rid9">9</a>].</p><p>The rationale for anticoagulation in acute pylephlebitis is to prevent sequelae of thrombus extension. Most of the evidence informing the impact of anticoagulation is from small observational studies and of low quality. In one report of 100 patients with pylephlebitis, among whom 35 received anticoagulation, anticoagulation was associated with a lower mortality rate (6 versus 22 percent) [<a href="#rid5">5</a>]. Similarly, in another retrospective study, none of the 12 patients who received anticoagulation died compared with 5 of the 32 who did not receive anticoagulation [<a href="#rid7">7</a>]. However, in one retrospective study of 67 patients, anticoagulation was associated with a higher rate of portal vein thrombus resolution (58 versus 21 percent) but was not independently associated with lower mortality after adjusting for severity of illness [<a href="#rid9">9</a>]. A case report of anticoagulation after extension of thrombus documented prompt resolution of the clot [<a href="#rid10">10</a>]. </p><p>Thrombolytic therapy for thrombosis progression has been reported [<a href="#rid10">10,41</a>], although we do not routinely pursue this. There is minimal clinical experience with thrombolysis for pylephlebitis and no conclusive evidence of efficacy.</p><p class="headingAnchor" id="H18"><span class="h2">Percutaneous techniques</span><span class="headingEndMark"> — </span>Catheter insertion into the portal vein with aspiration of thrombus and/or pus has been reported [<a href="#rid42">42,43</a>]. Intraportal infusion of antibiotics has also been described [<a href="#rid42">42</a>]. Further clinical experience is required before this technique can be routinely recommended.</p><p class="headingAnchor" id="H19"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Surgery is not usually required for the management of pylephlebitis. However, surgical drainage of the precipitating focus may be necessary in some cases.</p><p class="headingAnchor" id="H637173734"><span class="h1">FOLLOW UP</span><span class="headingEndMark"> — </span>We typically perform follow-up imaging (either computed tomography scanning or ultrasonography) of the portal vein approximately five to seven days following initiation of antibiotic therapy. Incomplete resolution of the thrombus is common and does not preclude clinical improvement [<a href="#rid5">5</a>]. However, repeat imaging can identify thrombus extension or other complications that may prompt changes in management. (See <a class="local">'Anticoagulation for select patients'</a> above.)</p><p>Screening endoscopy is not routinely performed because of pylephlebitis. However, it may be warranted if <em>Fusobacterium</em> bacteremia occurs in this setting, since this has been associated with occult gastrointestinal malignancy [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H20"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Pylephlebitis was uniformly fatal in the 20 cases reported in 1948, secondary to appendicitis [<a href="#rid12">12</a>]. Even with newer available antibiotics, the condition continues to have an appreciable mortality rate, ranging from 11 to 32 percent [<a href="#rid2">2,7,19</a>].</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Pylephlebitis is infective suppurative thrombosis of the portal vein and is associated with significant morbidity and mortality; it can complicate intra-abdominal sepsis of any etiology. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Pylephlebitis begins with thrombophlebitis of small veins draining an area of infection. Extension of the thrombophlebitis into larger veins leads to septic thrombophlebitis of the portal vein, which can extend further to involve the mesenteric veins. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – The most common predisposing infections leading to pylephlebitis are diverticulitis and appendicitis. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – Bacteremia, which is frequently polymicrobial, occurred in 88 percent of cases in one series; the most common bloodstream isolates were <em>Bacteroides fragilis</em> and <em>Escherichia coli</em>. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – Abdominal pain, which is not necessarily severe, and fever are the most common presenting symptoms of pylephlebitis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of pylephlebitis requires the demonstration of portal vein thrombosis (pylethrombosis) usually accompanied by bacteremia in a febrile patient. We prefer the computed tomography (CT) scan as the imaging study because of the additional ability to identify an underlying focus of infection elsewhere in the abdomen or pelvis (<a class="graphic graphic_diagnosticimage graphicRef91203" href="/d/graphic/91203.html" rel="external">image 1</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Empiric antibiotic selection</strong> – Treatment of pylephlebitis involves empiric antibiotic therapy; until culture results are available, we suggest empiric treatment with a parenteral regimen with broad gram-negative and anaerobic coverage (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Typical treatment regimens include one of the following (see <a class="local">'Antibiotics'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Combination therapy with <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg every eight hours) PLUS one of the following, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (2 g daily) OR <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> (2 g every six hours) OR <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (400 mg every 12 hours) OR <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> (500 mg daily)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> (4.5 g every six hours) OR <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> (3 g every six hours)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Monotherapy with a carbapenem, such as, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> (500 mg every six hours) OR <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> (1 g every eight hours) OR <a class="drug drug_general" data-topicid="8675" href="/d/drug information/8675.html" rel="external">ertapenem</a> (1 g daily)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tailored antibiotic therapy</strong> – The initial antibiotic choice should be modified once culture results and antimicrobial susceptibility testing are available. (See <a class="local">'Recommended regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of antibiotics</strong> – The typical duration of antibiotic therapy is at least four to six weeks. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role of anticoagulation</strong> – We do not routinely use anticoagulation for pylephlebitis. However, for patients with progression of thrombosis on repeat imaging or persistent fever or bacteremia despite antibiotic therapy, we suggest anticoagulation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Thrombosis extension into the mesenteric vein on initial evaluation, a hypercoagulable state, and isolation of <em>Bacteroides</em> spp are other potential indications for anticoagulation. We continue anticoagulation until the patient has clinically improved and imaging documents stability of the thrombus without extension. (See <a class="local">'Anticoagulation for select patients'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Saxena R, Adolph M, Ziegler JR, et al. Pylephlebitis: a case report and review of outcome in the antibiotic era. Am J Gastroenterol 1996; 91:1251.</a></li><li><a class="nounderline abstract_t">Plemmons RM, Dooley DP, Longfield RN. Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect Dis 1995; 21:1114.</a></li><li><a class="nounderline abstract_t">Fusaro L, Di Bella S, Martingano P, et al. Pylephlebitis: A Systematic Review on Etiology, Diagnosis, and Treatment of Infective Portal Vein Thrombosis. Diagnostics (Basel) 2023; 13.</a></li><li><a class="nounderline abstract_t">Kasper DL, Sahani D, Misdraji J. Case records of the Massachusetts General Hospital. Case 25-2005. A 40-year-old man with prolonged fever and weight loss. N Engl J Med 2005; 353:713.</a></li><li><a class="nounderline abstract_t">Kanellopoulou T, Alexopoulou A, Theodossiades G, et al. Pylephlebitis: an overview of non-cirrhotic cases and factors related to outcome. Scand J Infect Dis 2010; 42:804.</a></li><li><a class="nounderline abstract_t">Pradka SP, Trankiem CT, Ricotta JJ. Pylephlebitis and acute mesenteric ischemia in a young man with inherited thrombophilia and suspected foodborne illness. J Vasc Surg 2012; 55:1769.</a></li><li><a class="nounderline abstract_t">Baril N, Wren S, Radin R, et al. The role of anticoagulation in pylephlebitis. Am J Surg 1996; 172:449.</a></li><li><a class="nounderline abstract_t">Zardi EM, Giorgi C, Zardi DM. Pylephlebitis as a Complication of Cholangitis and Sepsis in an HIV-Positive Patient. Dig Dis Sci 2019; 64:1719.</a></li><li><a class="nounderline abstract_t">Naymagon L, Tremblay D, Schiano T, Mascarenhas J. The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes. J Thromb Thrombolysis 2020; 49:325.</a></li><li><a class="nounderline abstract_t">Duffy FJ Jr, Millan MT, Schoetz DJ Jr, Larsen CR. Suppurative pylephlebitis and pylethrombosis: the role of anticoagulation. Am Surg 1995; 61:1041.</a></li><li><a class="nounderline abstract_t">Joly V, Belmatoug N, Sibert A, et al. Septic thrombophlebitis of the portal vein. Clin Infect Dis 1996; 23:417.</a></li><li><a class="nounderline abstract_t">SORO Y. Pylephlebitis and liver abscesses due to appendicitis. J Int Coll Surg 1948; 11:464.</a></li><li><a class="nounderline abstract_t">Tsao YT, Lin SH, Cheng CJ, Chang FY. Pylephlebitis associated with acute infected choledocholithiasis. Am J Med Sci 2006; 332:85.</a></li><li><a class="nounderline abstract_t">Tung JY, Johnson JL, Liacouras CA. Portal-mesenteric pylephlebitis with hepatic abscesses in a patient with Crohn's disease treated successfully with anticoagulation and antibiotics. J Pediatr Gastroenterol Nutr 1996; 23:474.</a></li><li><a class="nounderline abstract_t">Baddley JW, Singh D, Correa P, Persich NJ. Crohn's disease presenting as septic thrombophlebitis of the portal vein (pylephlebitis): case report and review of the literature. Am J Gastroenterol 1999; 94:847.</a></li><li><a class="nounderline abstract_t">Shin AR, Lee CK, Kim HJ, et al. Septic pylephlebitis as a rare complication of Crohn's disease. Korean J Gastroenterol 2013; 61:219.</a></li><li><a class="nounderline abstract_t">Scaringi S, Giudici F, Gabbani G, et al. Pylephlebitis and Crohn's disease: A rare case of septic shock. Int J Surg Case Rep 2017; 39:106.</a></li><li><a class="nounderline abstract_t">Hamera L, Abraham S, Jordan J. Pylephlebitis as a Rare Complication of Ulcerative Colitis: A Case Report. Cureus 2019; 11:e4792.</a></li><li><a class="nounderline abstract_t">Choudhry AJ, Baghdadi YM, Amr MA, et al. Pylephlebitis: a Review of 95 Cases. J Gastrointest Surg 2016; 20:656.</a></li><li><a class="nounderline abstract_t">Chau NG, Bhatia S, Raman M. Pylephlebitis and pyogenic liver abscesses: a complication of hemorrhoidal banding. Can J Gastroenterol 2007; 21:601.</a></li><li><a class="nounderline abstract_t">Díaz-Cuervo F, Posada-Calderon L, Ramirez-Rodríguez N, et al. Pylephlebitis with splenic abscess following transrectal prostate biopsy: rare complications of intra-abdominal infection. J Surg Case Rep 2017; 2017:rjw075.</a></li><li><a class="nounderline abstract_t">Saito Y, Nishizawa T, Arioka H. Pylephlebitis after sigmoid colonic polypectomy. BMJ Case Rep 2022; 15.</a></li><li><a class="nounderline abstract_t">De Roover A, Detry O, Coimbra C, et al. Pylephlebitis of the portal vein complicating intragastric migration of an adjustable gastric band. Obes Surg 2006; 16:369.</a></li><li><a class="nounderline abstract_t">Tandon R, Davidoff A, Worthington MG, Ross JJ. Pylephlebitis after CT-guided percutaneous liver biopsy. AJR Am J Roentgenol 2005; 184:S70.</a></li><li><a class="nounderline abstract_t">Stone NR, Martin T, Biswas J, et al. Bacteroides-associated pylephlebitis in a patient with strongyloidiasis. Am J Trop Med Hyg 2015; 92:340.</a></li><li><a class="nounderline abstract_t">Wang YF, Chang CC, Lee TC, et al. Recent trend of pylephlebitis in Taiwan: Klebsiella pneumoniae liver abscess as an emerging etiology. Infection 2013; 41:1137.</a></li><li><a class="nounderline abstract_t">Mellor TE, Mitchell N, Logan J. Lemierre's syndrome variant of the gut. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Hale GR, Sakkal LA, Galanis T. Pylephlebitis treated with apixaban. Hosp Pract (1995) 2019; 47:192.</a></li><li><a class="nounderline abstract_t">Abughanimeh O, Tahboub M, Zafar Y, Abu Ghanimeh M. Pylephlebitis Caused by Actinomyces Bacteremia. Cureus 2018; 10:e2887.</a></li><li><a class="nounderline abstract_t">Phoompoung P, Chayakulkeeree M, Ngamskulrungroj P, Pongpaibul A. Asymptomatic Histoplasma Pylephlebitis in an Orthotopic Liver Transplant Recipient: A Case Report and Literature Review. Mycopathologia 2019; 184:177.</a></li><li><a class="nounderline abstract_t">Sakamoto H, Suga M, Ozeki I, et al. Subcapsular hematoma of the liver and pylethrombosis in the setting of cholestatic liver injury. J Gastroenterol 1996; 31:880.</a></li><li><a class="nounderline abstract_t">Farin P, Paajanen H, Miettinen P. Intraoperative US diagnosis of pylephlebitis (portal vein thrombosis) as a complication of appendicitis: a case report. Abdom Imaging 1997; 22:401.</a></li><li><a class="nounderline abstract_t">Wireko M, Berry PA, Brennan J, Aga R. Unrecognized pylephlebitis causing life-threatening septic shock: a case report. World J Gastroenterol 2005; 11:614.</a></li><li><a class="nounderline abstract_t">Dean JW, Trerotola SO, Harris VJ, et al. Percutaneous management of suppurative pylephlebitis. J Vasc Interv Radiol 1995; 6:585.</a></li><li><a class="nounderline abstract_t">Nishimori H, Ezoe E, Ura H, et al. Septic thrombophlebitis of the portal and superior mesenteric veins as a complication of appendicitis: report of a case. Surg Today 2004; 34:173.</a></li><li><a class="nounderline abstract_t">Brown KT, Gandhi RT, Covey AM, et al. Pylephlebitis and liver abscess mimicking hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003; 2:221.</a></li><li><a class="nounderline abstract_t">Chang TN, Tang L, Keller K, et al. Pylephlebitis, portal-mesenteric thrombosis, and multiple liver abscesses owing to perforated appendicitis. J Pediatr Surg 2001; 36:E19.</a></li><li><a class="nounderline abstract_t">Balthazar EJ, Gollapudi P. Septic thrombophlebitis of the mesenteric and portal veins: CT imaging. J Comput Assist Tomogr 2000; 24:755.</a></li><li><a class="nounderline abstract_t">Bleeker-Rovers CP, Jager G, Tack CJ, et al. F-18-fluorodeoxyglucose positron emission tomography leading to a diagnosis of septic thrombophlebitis of the portal vein: description of a case history and review of the literature. J Intern Med 2004; 255:419.</a></li><li><a class="nounderline abstract_t">Perez-Cruet MJ, Grable E, Drapkin MS, et al. Pylephlebitis associated with diverticulitis. South Med J 1993; 86:578.</a></li><li><a class="nounderline abstract_t">Sherigar R, Amir KA, Bobba RK, et al. Abdominal pain secondary to pylephlebitis: an uncommon disease of the portal venous system, treated with local thrombolytic therapy. Dig Dis Sci 2005; 50:983.</a></li><li><a class="nounderline abstract_t">Vivas I, Bilbao JI, Martínez-Cuesta A, et al. Combination of various percutaneous techniques in the treatment of pylephlebitis. J Vasc Interv Radiol 2000; 11:777.</a></li><li><a class="nounderline abstract_t">Pelsang RE, Johlin F, Dhadha R, et al. Management of suppurative pylephlebitis by percutaneous drainage: placing a drainage catheter into the portal vein. Am J Gastroenterol 2001; 96:3192.</a></li></ol></div><div id="topicVersionRevision">Topic 2713 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651182" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pylephlebitis: a case report and review of outcome in the antibiotic era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589130" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36766534" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pylephlebitis: A Systematic Review on Etiology, Diagnosis, and Treatment of Infective Portal Vein Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16107625" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Case records of the Massachusetts General Hospital. Case 25-2005. A 40-year-old man with prolonged fever and weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20735334" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pylephlebitis: an overview of non-cirrhotic cases and factors related to outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22520365" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pylephlebitis and acute mesenteric ischemia in a young man with inherited thrombophilia and suspected foodborne illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8942542" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The role of anticoagulation in pylephlebitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30488240" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pylephlebitis as a Complication of Cholangitis and Sepsis in an HIV-Positive Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31493290" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486441" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Suppurative pylephlebitis and pylethrombosis: the role of anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8842302" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Septic thrombophlebitis of the portal vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18885819" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pylephlebitis and liver abscesses due to appendicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16909055" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pylephlebitis associated with acute infected choledocholithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8956191" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Portal-mesenteric pylephlebitis with hepatic abscesses in a patient with Crohn's disease treated successfully with anticoagulation and antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086679" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Crohn's disease presenting as septic thrombophlebitis of the portal vein (pylephlebitis): case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23624737" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Septic pylephlebitis as a rare complication of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28826071" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pylephlebitis and Crohn's disease: A rare case of septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31384516" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pylephlebitis as a Rare Complication of Ulcerative Colitis: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26160320" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pylephlebitis: a Review of 95 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17853956" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pylephlebitis and pyogenic liver abscesses: a complication of hemorrhoidal banding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28775833" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pylephlebitis with splenic abscess following transrectal prostate biopsy: rare complications of intra-abdominal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36524262" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pylephlebitis after sigmoid colonic polypectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16545171" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pylephlebitis of the portal vein complicating intragastric migration of an adjustable gastric band.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728028" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pylephlebitis after CT-guided percutaneous liver biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25510718" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bacteroides-associated pylephlebitis in a patient with strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23817997" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recent trend of pylephlebitis in Taiwan: Klebsiella pneumoniae liver abscess as an emerging etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29054895" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lemierre's syndrome variant of the gut.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31545676" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pylephlebitis treated with apixaban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30155389" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pylephlebitis Caused by Actinomyces Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29789991" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Asymptomatic Histoplasma Pylephlebitis in an Orthotopic Liver Transplant Recipient: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9027656" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Subcapsular hematoma of the liver and pylethrombosis in the setting of cholestatic liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9157860" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intraoperative US diagnosis of pylephlebitis (portal vein thrombosis) as a complication of appendicitis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15641159" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Unrecognized pylephlebitis causing life-threatening septic shock: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579869" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Percutaneous management of suppurative pylephlebitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14745623" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Septic thrombophlebitis of the portal and superior mesenteric veins as a complication of appendicitis: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14599973" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pylephlebitis and liver abscess mimicking hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528636" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pylephlebitis, portal-mesenteric thrombosis, and multiple liver abscesses owing to perforated appendicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11045699" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Septic thrombophlebitis of the mesenteric and portal veins: CT imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871467" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : F-18-fluorodeoxyglucose positron emission tomography leading to a diagnosis of septic thrombophlebitis of the portal vein: description of a case history and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8488411" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pylephlebitis associated with diverticulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15906779" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Abdominal pain secondary to pylephlebitis: an uncommon disease of the portal venous system, treated with local thrombolytic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10877426" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Combination of various percutaneous techniques in the treatment of pylephlebitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11721772" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Management of suppurative pylephlebitis by percutaneous drainage: placing a drainage catheter into the portal vein.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
